Business Wire

Loomis Sayles Announces Changes to Disciplined Alpha Team

Share

Loomis, Sayles & Company, the global investment manager with nearly $390 billion in assets under management as of 31 March 2025, has announced that Lynne Royer, co-head and portfolio manager of the Disciplined Alpha Team, will retire at the end of 2025 following a remarkable investment career spanning four decades. Additionally, longtime portfolio manager Brad Stevens, CFA, has been promoted to co-head of the team alongside Lynne and Seth Timen, who has co-led the team since 2021.

Known for an intense focus on relative value investing and a proprietary risk-adjusted framework for making security selection decisions, the Disciplined Alpha Team manages over $22 billion in assets as of 31 March 2025.

Lynne will step down from her portfolio management and team co-head roles in October 2025 and will serve as senior advisor to the team through the end of December. Brad and Seth will work closely together on the oversight of Disciplined Alpha portfolios, as well as management of the team, leveraging Seth’s extensive fixed income trading experience and Brad’s fundamental research roots.

Since joining Loomis Sayles in 2010 as a credit analyst, Brad has consistently demonstrated leadership, investment excellence and a deep commitment to Disciplined Alpha’s distinct investment philosophy. Following a promotion to senior credit analyst, in 2018 he was named a credit portfolio manager responsible for idea generation and security selection, a role he will retain for select industries while transferring some sector coverage to others.

“Among Lynne’s many contributions to Loomis Sayles was effectively building a deep bench of investment professionals for the Disciplined Alpha Team together with Seth,” said David Waldman, chief investment officer of Loomis Sayles. “Brad’s promotion is well-earned and represents a natural next step for the team, which is positioned to continue delivering strong results for clients under his and Seth’s leadership.”

Lynne began her investment career in 1985 and joined Loomis Sayles as the co-head and co-founder of the Disciplined Alpha platform in 2010. In addition to shaping the team’s investment philosophy and approach, Lynne contributed significantly to Loomis Sayles’ culture as co-founder of the firm’s first employee resource group, Women@Work.

“Over the last 15 years, Lynne’s leadership has been a driving force behind the growth of the Disciplined Alpha Team’s best-in-class product platform,” said Kevin Charleston, chief executive officer of Loomis Sayles. “We are immensely grateful for Lynne’s dedication to both clients and colleagues and wish her the best as she pursues her passions in retirement.”

ABOUT BRADLEY STEVENS, CFA

Brad Stevens is a portfolio manager and co-head of the Disciplined Alpha Team at Loomis, Sayles & Company. Prior to being named co-head of the team in 2025, Brad was a credit portfolio manager on the team, responsible for idea generation and security selection within his sectors. Brad began his investment industry career in 2000. Prior to joining Loomis Sayles in 2010, he worked at the California Public Employees’ Retirement System as an investment officer in credit. Prior to this, Brad traded equity options at Timber Hill LLC. He earned a BA in economics from Denison University and an MBA from Columbia Business School. Brad is a CFA® charterholder.

ABOUT SETH TIMEN

Seth Timen is a portfolio manager and co-head of the Disciplined Alpha Team at Loomis, Sayles & Company. Seth was named co-head of the team in 2020. He began his investment industry career in 2001 and joined Loomis Sayles in 2010 from Pequot Capital Management, where he was responsible for trading fixed income risk across investment grade, high yield, and structured products. Previously, Seth was an associate at Credit Suisse, where he assisted with corporate bond investment and strategy execution for institutional clients. He earned a BA from the University of Michigan.

ABOUT LOOMIS SAYLES

Since 1926, Loomis, Sayles & Company has helped fulfill the investment needs of institutional and mutual fund clients worldwide. The firm’s performance-driven investors integrate deep proprietary research and risk analysis to make informed, judicious decisions. Teams of portfolio managers, strategists, research analysts and traders collaborate to assess market sectors and identify investment opportunities wherever they may lie, within traditional asset classes or among a range of alternative investments. Loomis Sayles has the resources, foresight and the flexibility to look far and wide for value in broad and narrow markets in its commitment to deliver attractive, risk-adjusted returns for clients. This rich tradition has earned Loomis Sayles the trust and respect of clients worldwide, for whom it manages $390.1 billion* in assets (as of 31 March 2025).

*Includes the assets of both Loomis, Sayles & Co., LP, and Loomis Sayles Trust Company, LLC. ($33.9 billion for the Loomis Sayles Trust Company). Loomis Sayles Trust Company is a wholly owned subsidiary of Loomis, Sayles & Company, L.P.

SAIFiitxkace

View source version on businesswire.com: https://www.businesswire.com/news/home/20250519835097/en/

Contacts

Kate Sheehan
(617) 960-4447
ksheehan@loomissayles.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 23:30:00 EEST | Press release

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved o

IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 23:05:00 EEST | Press release

IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global freight industry. “Einride shares our belief that quantum computing will fundamentally reshape and improve how large industries such as transportation and logistics operate,” said Niccolo de Masi, CEO of IonQ. “This partnership is aimed at creating a powerful platform with u

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 22:26:00 EEST | Press release

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop

NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 22:24:00 EEST | Press release

NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates

Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 22:08:00 EEST | Press release

As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye